Quantcast

Latest HUMIRA Stories

2009-09-08 09:11:00

NEW YORK, Sept. 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Prescription Drugs http://www.reportlinker.com/p0131233/Prescription-Drugs.html This report analyzes the worldwide markets for Prescription Drugs in US$ Billion by the following therapeutic class - Oncologics/ Cancer Drugs, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists,...

2009-09-08 08:59:00

NEW YORK, Sept. 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. FoodService Disposables http://www.reportlinker.com/p0131234/FoodService-Disposables.html This report analyzes the US market for FoodService Disposables in Millions of US$ by the following Product Types: Cups and Lids, Containers, Dinnerware, Napkins, and Others. This report also analyzes the US Market for Foodservice Disposables by End-Use Segments: Restaurants,...

2009-07-15 06:48:00

ABBOTT PARK, Ill., July 15 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2009. Diluted earnings per share, excluding specified items, were $0.89, at the high end of Abbott's second-quarter guidance range of $0.87 to $0.89. Diluted earnings per share under Generally Accepted Accounting Principles (GAAP) were $0.83. Worldwide operational sales, which excludes an unfavorable 8.0 percent effect of exchange rates,...

2009-06-30 14:16:54

The U.S. District Court in Marshall, Texas, ordered Abbott Laboratories to pay Johnson & Johnson $1.7 billion in patent-related damages. Attorneys for Johnson & Johnson said Abbott's rheumatoid arthritis drug Humira, one of the top-selling drugs in the world, was made using technology developed exclusively for Johnson & Johnson at New York University. Humira earned more than $4 billion in sales in 2008. It differs from Johnson & Johnson's product Remicade, as it is fully...

2009-04-30 10:49:00

Newly Approved Simponi is Expected to Achieve Strong Uptake in this Niche Market, According to a New Report from Decision Resources WALTHAM, Mass., April 30 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the availability of Amgen/Wyeth/Takeda's Enbrel, Centocor/Schering-Plough/Mitsubishi Tanabe's Remicade, and Abbott/Eisai's Humira has driven dramatic growth in the spondyloarthropathy (SpA)...

2009-04-15 06:17:00

- Adjusted EPS Growth of 15.9 Percent (GAAP EPS Growth of 53.3 Percent) - - Confirms Double-Digit EPS Guidance Range for 2009 - - Increased 2009 Dividend by 11 Percent - ABBOTT PARK, Ill., April 15 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2009. Diluted earnings per share, excluding specified items, were $0.73, reflecting 15.9 percent growth, and $0.03 above the mid-point of Abbott's previous first-quarter...

2009-01-26 07:00:00

Humira Will Retain its Status as Decision Resources' Clinical Gold Standard for Crohn's Disease Through 2017, According to a New Report from Decision Resources WALTHAM, Mass., Jan. 26, /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed gastroenterologists say that a therapy's effect on maintenance of clinical remission is the attribute that most influences their choice in prescribing a...

2009-01-21 06:32:00

ABBOTT PARK, Ill., Jan. 21 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2008. -- Diluted earnings per share, excluding specified items, were $1.06, reflecting 14.0 percent growth, in line with Abbott's previous forecast. Diluted earnings per share under Generally Accepted Accounting Principles (GAAP) were $0.98, up 27.3 percent. -- Worldwide sales increased 10.1 percent...

2008-12-02 07:00:00

Percentage of Biologic-Treated Psoriasis Patients Will Double by 2017, According to a New Report from Decision Resources WALTHAM, Mass., Dec. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that biologic agents, particularly Centocor/Janssen-Cilag's Stelara and Abbott/Eisai's Humira, will drive the moderate to severe psoriasis drug market to more than double to nearly $5 billion over the next decade....

2008-12-01 07:00:00

Increased Uptake of Current Agents and Emergence of New Therapies Will Drive Robust Annual Market Growth, According to a New Report from Decision Resources WALTHAM, Mass., Dec. 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Abbott/Eisai's Humira is poised to overtake Centocor/Schering-Plough/Mitsubishi Tanabe's Remicade as the Crohn's disease market leader by 2012. Humira will retain its...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.